Humacyte, Inc.
Clinical trials sponsored by Humacyte, Inc., explained in plain language.
A biotech company developing bioengineered human tissues and organs.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Lab-Grown vessel could save Teens' limbs after severe injury
Disease control Not yet recruitingThis trial tests whether a lab-grown blood vessel called SYMVESS can safely repair damaged arteries in the arms or legs of adolescents when their own veins aren't suitable. The study enrolls teens up to age 17 with severe arterial injuries that threaten limb loss. Participants re…
Phase: PHASE3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Lab-Grown artery save injured limbs?
Disease control Not yet recruitingThis study is testing a lab-grown blood vessel called Symvess in adults who have suffered a serious injury to an artery in their arm or leg. The goal is to see how well the vessel stays open and functions over a year, and whether it helps avoid amputation and infection. Participa…
Phase: PHASE4 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could Lab-Grown arteries replace vein grafts in heart bypass surgery?
Disease control Not yet recruitingThis trial tests whether a lab-grown, tissue-engineered blood vessel can be safely used as a bypass graft in people with coronary artery disease undergoing heart bypass surgery. Ten participants will receive the artificial vessel alongside a standard graft, and researchers will m…
Phase: PHASE2 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC